SonoMind Raises €20M Series A for Focused Ultrasound Neuromodulation in Depression
Summary
SonoMind has raised €20 million ($23 million) in a Series A funding round led by Critical Path Ventures and Bpifrance through its French Tech Seed and Deep Tech 2030 funds. The company is developing non-invasive focused ultrasound neuromodulation to precisely stimulate deep brain regions for treatment-resistant depression. Preliminary clinical results from Sainte-Anne Hospital showed more than 60% reduction in symptom severity after five consecutive daily sessions with no significant adverse effects. The funding will support randomized, double-blind, multicenter trials with marketing authorization targeted by 2029.
Why it matters
This funding positions SonoMind at the forefront of a next-generation neuromodulation modality that could overcome limitations of existing non-invasive approaches. While TMS and tDCS have shown efficacy in depression, they cannot reliably reach deep brain structures involved in mood regulation. Focused ultrasound offers both depth and precision without surgery, potentially expanding access to neuromodulation therapy for the 30-50% of depression patients who do not respond to first-line treatments. The strong preliminary clinical data supports further investigation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial